Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

131.26 -0.65 (-0.49%)

Official Closing Price Updated: 7:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

38 39 Next >

Novartis Drug Shows Improvement In Sjögren's Disease In Late-Stage Trials: Analyst Deems Data Positive For Zura Bio As Well ↗

August 11, 2025

Novartis now sees the potential for the drug to become the first and only targeted treatment approved for patients with the disease.

Via Stocktwits

Novartis' Investigational Drug Aces Two Pivotal Trials For Chronic Disease Impacting Tears, Saliva ↗

August 11, 2025

Novartis' ianalumab showed significant disease activity improvement in two Phase 3 Sjögren's trials, supporting plans for global health authority filings.

Via Benzinga

Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79% ↗

August 08, 2025

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales outlook after Q2 beat.

Via Benzinga

2 Brilliant Vanguard Index Funds to Buy With $1,000 in August and Hold Forever ↗

August 08, 2025

These Vanguard index funds offer diversified exposure to many of the most influential stocks in the world.

Via The Motley Fool

Topics ETFs

Novartis Reportedly Eyeing To Acquire Avidity Biosciences: But Retail Expects Management To Sell Only At Significant Premium ↗

August 06, 2025

Via Stocktwits

Earnings Outlook For Novartis ↗

July 16, 2025

Via Benzinga

PTCT Earnings Beat but Sales Drop 4% ↗

August 07, 2025

Via The Motley Fool

Topics Earnings

Monte Rosa (GLUE) Q2 Revenue Jumps 394% ↗

August 07, 2025

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

Schrödinger (SDGR) Q2 2025 Earnings Transcript ↗

August 06, 2025

Via The Motley Fool

Novo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns Hopeful ↗

August 06, 2025

Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021.

Via Stocktwits

Topics Earnings

Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal ↗

August 06, 2025

The company is focused on treatments for forms of muscular dystrophy.

Via Investor's Business Daily

Novartis Fails To Block Heart Failure Drug’s Generic From Launching Through 2026: Report ↗

July 11, 2025

Via Stocktwits

Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave

August 04, 2025

In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch ↗

July 31, 2025

Via Stocktwits

Topics Government

3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs ↗

July 25, 2025

US President Trump imposed 200% tariff on pharmaceuticals affecting US drug prices and supply chain, but analysts say it may not happen soon.

Via Benzinga

Topics Economy Government World Trade

Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy ↗

July 25, 2025

Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients.

Via Benzinga

U.S. Current-Account Deficit Widens to $450 Billion Amid Trade Imbalances and Energy Imports

July 25, 2025

The United States current-account deficit expanded sharply to $450 billion in the first half of 2025, marking a renewed widening of the country's financial shortfall with the rest of the world. This...

Via MarketMinute

Topics Artificial Intelligence Economy Supply Chain

NOVARTIS AG-SPONSORED ADR (NYSE:NVS): A Top Dividend Stock with Strong Profitability and Financial Stability ↗

July 25, 2025

NOVARTIS AG (NVS) is a top dividend stock with a 3.76% yield, strong profitability, and financial stability, making it ideal for income-focused investors.

Via Chartmill

The Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent' For Gene Therapies. ↗

July 24, 2025

Sarepta stock is now trading at a nine-year low as the debacle with its gene therapy, Elevidys, continues.

Via Investor's Business Daily

Topics Death Workforce

Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US ↗

July 22, 2025

AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.

Via Benzinga

Topics Government

Highest Ever for This International Stock ETF -- But Analysts Say It Has Room to Run ↗

July 22, 2025

Via The Motley Fool

Topics ETFs World Trade

AstraZeneca Bets Big On America With $50B Investment, New Virginia Hub Plans Amid Pharma Tariff Jitters ↗

July 21, 2025

At the center of the company’s plan is a new, multi-billion-dollar manufacturing facility in Virginia.

Via Stocktwits

Topics Artificial Intelligence Government World Trade

Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm. ↗

July 20, 2025

Via The Motley Fool

Topics Government World Trade

NOVARTIS AG-SPONSORED ADR (NYSE:NVS) – A Potentially Undervalued Stock With Strong Fundamentals ↗

July 19, 2025

NOVARTIS AG (NYSE:NVS) presents a value opportunity with strong profitability, financial health, and reasonable growth, trading below industry and market valuations.

Via Chartmill

Novartis Makes A Bearish Move As One Of Its Bread-And-Butter Drugs Misses ↗

July 17, 2025

The company's second biggest product missed sales expectations. Shares look likely to undercut a buy zone.

Via Investor's Business Daily

Topics Government Stocks

Novartis Trims Operating Income Outlook After Strong Q2 Performance, Initiates $10 Billion Stock Buyback ↗

July 17, 2025

Novartis posts solid Q2 results, raises 2025 earnings outlook, launches $10 billion share buyback, and announces CFO succession plan amid strong drug sales.

Via Benzinga

Earnings Scheduled For July 17, 2025 ↗

July 17, 2025

Via Benzinga

Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' ↗

July 16, 2025

Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.

Via Benzinga

Topics Government World Trade

Divi’s Labs Shares Dip After Patent Loss: SEBI RA Recommends Buy On Dips ↗

July 14, 2025

The stock slid to an intraday low of ₹6,545 on Monday following a gap-down open, as investors reacted to MSN’s legal win over Entresto.

Via Stocktwits

Topics Intellectual Property

This Dividend ETF Is Near Its Highest Level Ever -- Is It Too Late to Invest in It? ↗

July 12, 2025

Via The Motley Fool

Topics ETFs

< Previous 1 2 3 4 5 6 7 8 9

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.